20768-14-3

Upstream product

• 100-02-7 4-nitro-phenol 
• 107-59-5 tert-Butyl chloroacetate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 1798-11-4 4-nitrophenoxyacetic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 174774-57-3 tert-butyl 4-(methylamino)phenoxyacetate 
• 207445-12-3 {(S)-2-[(R)-1-(4-tert-Butoxycarbonylmethoxy-phenylcarbamoyl)-2-phenyl-ethylcarbamoyl]-pyrrolidin-1-yl}-oxo-acetic acid methyl ester 
• 207445-09-8 [4-((R)-2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-phenoxy]-acetic acid tert-butyl ester 
• 209258-95-7 [(S)-2-((R)-1-{[(4-tert-Butoxycarbonylmethoxy-phenylcarbamoyl)-methyl]-carbamoyl}-2-phenyl-ethylcarbamoyl)-pyrrolidin-1-yl]-oxo-acetic acid methyl ester 
• 209258-89-9 (S)-2-[(R)-1-(4-tert-Butoxycarbonylmethoxy-phenylcarbamoyl)-2-phenyl-ethylcarbamoyl]-pyrrolidine-1-carboxylic acid benzyl ester 
• 1026251-05-7 [(S)-2-((R)-1-{[(4-Carboxymethoxy-phenylcarbamoyl)-methyl]-carbamoyl}-2-phenyl-ethylcarbamoyl)-pyrrolidin-1-yl]-oxo-acetic acid methyl ester 
• 209258-74-2 (S)-1-{(2S,3S)-2-Hydroxy-3-[2-(4-nitro-phenoxy)-acetylamino]-4-phenyl-butyryl}-pyrrolidine-2-carboxylic acid tert-butylamide 

Relevant academic research and scientific papers

QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS

The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders

QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS

The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders

2,4-Pyrimidinediamine Compounds and Their Uses

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

PPAR AGONIST COMPOUNDS, PREPARATION AND USES

The present invention relates to novel PPAR agonist compounds as well as pharmaceutical compositions containing them. The compounds according to the invention are of quite particular therapeutic interest, notably for treating diabetes and/or dyslipidemias, as well as for preventing cardiovascular pathologies.

GLYCINE B ANTAGONISTS

The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

Conversion of the LXR-agonist TO-901317-From inverse to normal modulation of γ-secretase by addition of a carboxylic acid and a lipophilic anchor

TO-901317, a LXR agonist, is an inverse modulator of Alzheimer's disease associated γ-secretase. We synthesized TO-901317 analogous compound but replaced the hexafluorocarbinol moiety by an oxyacetic acid functionality and hypothesized that the replacemen

New selenyl linker for solid-phase synthesis of dehydropeptides

A novel linker possessing selenocyanate and masked carboxylic acid was developed for the solid-phase synthesis of dehydropeptides. This linker was used to demonstrate the synthesis of the model compound of RGD-conjugated dehydropeptide.

N-aryl N′-hydroxyguanidines, a new class of NO-donors after selective oxidation by nitric oxide synthases: Structure-activity relationship

The formation of nitric oxide (NO) was followed during the oxidation of 37 N-hydroxyguanidines or related derivatives, including 18 new N-aryl N′ -hydroxyguanidines, by recombinant inducible nitric oxide synthase (NOS II). Several N-aryl N′-hydroxyguanidines bearing a relatively small, electron-donating para subtituent, such as H, F, Cl, CH3, OH, OCH3, and NH2, led to NO formation rates between 8 and 41% of that of NO formation from the natural NOS substrate, Nω-hydroxy-L-arginine (NOHA). The characteristics of these reactions were very similar to those previously reported for the oxidation of NOHA by NOS: (i) the strict requirement of NOS containing (6R)-5,6,7,8-tetrahydro-L-biopterin, reduced nicotinamide adenine dinucleotide phosphate, and O2 for the oxidation to occur, (ii) the formation of NO and the corresponding urea in a 1:1 molar ratio, and (iii) a strong inhibitory effect of the classical NOS inhibitors such as Nω-nitro-L-arginine and S-ethyl-iso-thiourea. Structure-activity relationship studies showed that two structural factors are crucial for NO formation from compounds containing a C=NOH function. The first one is the presence of a monosubstituted N-hydroxyguanidine function, since disubstituted N-hydroxyguanidines, amidoximes, ketoximes, and aldoximes failed to produce NO. The second one is the presence of a N-phenyl ring bearing a relatively small, not electron-withdrawing para substituent that could favorably interact with a hydrophobic cavity close to the NOS catalytic site. The kcat value for NOS II-catalyzed oxidation of N-parafluorophenyl N′-hydroxyguanidine was 80% of that found for NOHA, and its kcat/Km value was only 9-fold lower than that of NOHA. Interestingly, the Km value found for NOS II-catalyzed oxidation of N-(3-thienyl) N′-hydroxyguanidine was 25 μM, almost identical to that of NOHA. Recombinant NOS I and NOS III also oxidize several N-aryl N′-hydroxyguanidines with the formation of NO, with a clearly different substrate specificity. The best substrates of the studied series for NOS I and NOS III were N-(para-hydroxyphenyl) and N-(meta-aminophenyl) N′-hydroxyguanidine, respectively. Among the studied compounds, the para-chlorophenyl and paramethylphenyl derivatives were selective substrates of NOS II. These results open the way toward a new class of selective NO donors after in situ oxidation by each NOS family.

SUBSTITUTED UREA DERIVATIVES AS CELL ADHESION INHIBITORS

Compounds of formula (II) where R 1 is in the para or meta position and is (A); R 2 and R 3 are each independently selected from hydrogen, nitro, C 1-6 alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkoxyl, C 1-6 alkylamino, C 1-6 dialkylamino, C 1-6 akylC 1-4 alkoxyl, C 1-6 alkylaminoC 1-6 alkyl, amino, cyano, halogeno, trifluoromethyl, ?CO 2 R 12 and ?CONR 12 R 13 , where R 12 and R 13 are independently selected from hydrogen or C 1-6 alkyl, or R 2 and R 3 together with the phenyl to which they are attached form a 9 or 10 membered bicyclic ring system; R 4 is C 1-4 alkyl; R 5 is selected from hydrogen and C 1-4 alkyl; R 6 is selected from C 1-6 alkyl, C 1-4 alkyl(C 4-6 )cycloalkyl, C 1-6 alkyl(C 1-6 )alkoxyl, C 1-6 alkylS(C 1-6 )alkyl, C 1-4 alkylsulphonyl(C 1-4 )alkyl; (B) where q is an integer from 1 to 6 and R 14 is halogeno; R 7 is selected from C 1-6 alkyl, C 1-8 alkoxylcarbonyl, C 2-6 alkenyl, 1,3-benzodioxol-5-yl and aryl each optionally substituted by one or more substituents selected from C 1-4 alkoxy, C 1-6 alkyl, cyano, halogeno, and trifluoromethyl; R 8 is aryl, heteroaryl, a bicyclic heteroaryl ring system linked to the nitrogen via a ring carbon or a 9 or 10 membered bicyclic ring system linked to the nitrogen via a ring carbon and each ring is optionally substituted with up to two substituents, which may be the same or different, and are selected from C 1-6 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-6 alkylC 1-4 alkoxyl, C 1-6 alkylaminoC 1-6 alkyl, hydroxy, ?CO 2 H, ?(CH 2 ) p OH where p is 1 or 2, cyano, halogeno, and trifluoromethyl; R 9 and R 10 are each independently selected from hydrogen and C 1-4 alkyl or R 8 and R 9 together with the nitrogen to which they are attached form a dihydroindolyl, or a dihidroquinolinyl group; R 11 is selected from carboxyl, tetrazolyl, alkyl sulphonylcarbamyl, sulfo and sulfino; Y is oxygen, sulphur or sulfonyl; m is 0 or 1; and n is 0 or an integer from 1 to 4 with the proviso that when m and n cannot both be 0 and when m is 1, n is 0; or a pharmaceutically acceptable salt or in vivo hydrolyzable ester thereof. The compounds inhibit the interaction of vascular cell-adhesion molecule-1 and fibronectin with integrin very late antigen 4 (a 4 b 1 ). They have therapeutic applications such as in multiple sclerosis, rheumatoid arthritis, asthma, coronary artery disease and psoriasis

Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 1. The selection of naphthalene derivatives

The synthesis and design using molecular modeling techniques for non- peptide, low molecular weight novel fibrinogen receptor (glycoprotein IIb/IIIa: Gp IIb/IIIa) antagonists, is reported. We used a highly potent serine protease inhibitor, Nafamostat, having an amidinonaphthyl unit as the starting compound. The compounds 4-(6-amidino-2- naphthylaminocarbonyl)phenoxyacetic acid (5a) and 4-(6-amidino-2- naphthalenecarboxamido)phenoxyacetic acid (5b) inhibited adenosin-5'- diphospate (ADP)-induced aggregation of human platelet-rich plasma (PRP) with IC50 values of 0,05 and 0.07 μM, respectively, and had lost their ability to inhibit a variety of serine proteases, including thrombin, factor Xa, plasmin and trypsin.